The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
The subcutaneous combination of the BCMA-targeting bispecific antibody teclistamab and daratumumab produced promising preliminary efficacy and favorable tolerability in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results from the phase 1b TRIMM-2 trial.
Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.
Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.
A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma.
Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.
Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.
Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.